Deborah L Keller
CIK 1352992 · CEO, Covance Drug Development · last filed 2026-05-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.36M
Companies
3
Total Filings
41
Lifetime Open-Market Net
-$5.91M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Recent Filings · Page 3 of 5
41 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-02-20 | COVANCE INC (CVD) Delisted | Mixed | +10,997 | -$47.2K | EDGAR |
| 2014-02-11 | COVANCE INC (CVD) Delisted | Mixed | −3,065 | -$948.4K | EDGAR |
| 2013-12-19 | COVANCE INC (CVD) Delisted | Tax (F) | −2,545 | -$214.6K | EDGAR |
| 2013-08-23 | COVANCE INC (CVD) Delisted | Mixed | −1,200 | -$491.6K | EDGAR |
| 2013-02-21 | COVANCE INC (CVD) Delisted | Mixed | +10,398 | -$10.5K | EDGAR |
| 2012-12-20 | COVANCE INC (CVD) Delisted | Tax (F) | −1,491 | -$87.8K | EDGAR |
| 2012-11-20 | COVANCE INC (CVD) Delisted | Sell (S) | −2,962 | -$161.6K | EDGAR |
| 2012-02-22 | COVANCE INC (CVD) Delisted | Mixed | +12,774 | -$5.9K | EDGAR |
| 2011-12-20 | COVANCE INC (CVD) Delisted | Tax (F) | −1,344 | -$59.9K | EDGAR |
| 2011-04-01 | COVANCE INC (CVD) Delisted | Mixed | −7,618 | -$513.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.